ESICM News

CLINICAL TRIALS IN INTENSIVE CARE

CLINICAL TRIALS IN INTENSIVE CARE

RESULTS FROM SIX HIGHLY ANTICIPATED RCTs

This first daily Thematic Session at LIVES 2015 focuses on clinical trials in intensive care, with results presented for the first time and published simultaneously in major scientific journals. Chaired by ESICM President-elect Massimo Antonelli, (Rome, Italy) and ICM Editor-In-Chief Elie Azoulay, (Paris, France), this cutting-edge session features a number of timely and topical clinical trials:

 

Long term effects of remote ischaemic preconditioning in high-risk patients undergoing cardiac surgery: Follow-up of a randomised clinical trial

In a multicentre randomised trial, we found that remote ischaemic preconditioning (RIPC) reduced acute kidney injury (AKI) in high risk patients undergoing cardiac surgery. In this follow-up study to the RenalRIPC trial, we examined the effect of RIPC on the composite end-point of mortality, need for renal replacement therapy, and persistent renal dysfunction at 90 days (MAKE90). RIPC significantly reduced the 3-month incidence of a composite end point of all-cause mortality, need for renal replacement therapy, and persistent renal dysfunction in high risk patients undergoing cardiac surgery. Furthermore, RIPC enhanced renal recovery in patients with AKI.     ~ Alexander Zarbock  

    

One-year outcome after ICU discharge: The FROG-ICU trial  

Mortality in intensive care units (ICU) is very high and those who survive the ICU stay will face a vulnerable period with a post-ICU mortality higher than the general population. The French and euRopean Outcome reGistry in Intensive Care Unit (FROG-ICU) study describes one-year outcome and risk factors of death in more than 1600 ICU patients. Modifiable factors were found the day of ICU discharge that may allow to prevent vulnerability after ICU discharge.       ~ Alexandre Mebazaa 

 

Uniquely, this session will also include a cast of expert commentators, who will provide commentary following each presentation and serve as a catalyst for further discussion and thought on the results of this Clinical Trials Session. Here is a full list of presentations and expert commentators:

  • Long term effects of remote ischaemic preconditioning in high-risk patients undergoing cardiac surgery: Follow-up of a randomised clinical trial -
    • Speaker: Alexander Zarbock, Münster, Germany
    • Commentator: Derek Angus, Pittsburgh, United States
  • Upper limb remote ischaemic preconditioning does not show a relevant benefit in elective cardiac surgery    
    • Speaker: Patrick Meybohm, Frankfurt, Germany
    • Commentator: Jean-Louis Vincent, Brussels, Belgium
  • One-year outcome after ICU discharge: The FROG-ICU trial    
    • Speaker: Alexandre Mebazaa, Paris, France
    • Commentator: Jean-François Timsit, Paris, France
  • Development and evaluation of strategies to improve sedation quality in intensive care: The DESIST trial    
    • Speaker: Timothy Walsh, Edinburgh, United Kingdom
    • Commentator: Giuseppe Citerio, Monza, Italy
  • Paracetamol for treatment of fever in ICU patients with likely infection    
    • Speaker: Paul Young, Wellington, New Zealand
    • Commentator: Howard Bauchner, Boston, United States
  • ICM - Inhaled nitric oxide for acute chest syndrome in adult sickle cell patients: A randomised controlled study    
    • Speaker: Bernard Maitre, Créteil, France
    • Commentator: Elie Azoulay, Paris, France

 

Join this exciting clinical trials session live...

Thematic Session ~ CLINICAL TRIALS IN INTENSIVE CARE  

05.10.2015, 16:00 – 18:00, room Berlin 

<Back to the news list
Comment on this news Comment on this news
To respond to this article, thank you for identifying
ReactionsReactions (0)